3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
12
Carcinoma, Hepatocellular
7
Neoplasm Metastasis
5
Colorectal Neoplasms
5
Esophageal Squamous Cell Carcinoma
4
Advanced Solid Tumor
4
Solid Tumor
3
Small Cell Lung Carcinoma
3
Lung Neoplasms
3
Esophageal Neoplasms
3
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Rectal Neoplasms
2
Melanoma
2
Cholangiocarcinoma
2
Carcinoma, Transitional Cell
2
Advanced Solid Tumour
2
Unresectable Stage III Non-small Cell Lung Cancer
1
Triple Negative Breast Neoplasms
1
Skin Neoplasms
1
Simpson-Golabi-Behmel syndrome
1
Patients With Initially Unresectable MSS-type Advanced Colorectal Cancer With Liver and/or Lung and Peritoneal Metastasis
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Nasopharyngeal Carcinoma
1
Metastatic Solid Tumors
1
Interventions
Fluorouracil
14
Nivolumab
13
Oxaliplatin
12
Leucovorin
11
Paclitaxel
7
Capecitabine
7
pembrolizumab
6
Radiotherapy
5
Cisplatin
5
Taxes
4
Specimen Handling
4
Radiation
4
Irinotecan
4
Drug Therapy
4
dehydroftorafur
3
Trastuzumab
3
Ramucirumab
3
Magnetic Resonance Spectroscopy
3
Folfox protocol
3
zimberelimab
2
zanidatamab
2
trastuzumab deruxtecan
2
futibatinib
2
Levoleucovorin
2
Endoscopy, Digestive System
2
Endoscopy
2
Carboplatin
2
Biopsy
2
zolbetuximab
1
trastuzumab biosimilar HLX02
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma Of Esophagus
×
tislelizumab
×
90 days
×
Clear all
NCT05152147
2026-05-19
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3
Active not recruiting
920 enrolled